From The Editor
-
Why RNA Is Good For Business
7/3/2023
Early last year, Nutcracker Therapeutics landed a $170 million Series C to further its work developing an RNA drug development platform. Learn how scientist-turned Chief Business Officer Geoff Nosrati is lifting the company above the cacophony of companies rallying around the therapeutic potential of RNA.
-
Key Biomanufacturing Ingredient In Short Supply
6/26/2023
Biopharma supply chains and manufacturing capacity are on the comeback trail, but one of the key requirements for sustainable development and manufacturing success remains elusive. NIIMBL Workforce Director John Balchunas shares perspective from a unique vantage point.
-
Considerations For Licensing Platforms From Universities
6/16/2023
Even the best platforms and technologies don’t come out of universities IND-ready. Just ask Coeptis Therapeutics, which recently licensed the novel CAR-T platform, SNAP-CAR, from the University of Pittsburgh. Coeptis’ Dave Mehalick, and Dan Yerace discuss the licensing agreement and the growing pains to expect when preparing a new platform for an IND.
-
Where Oncology Drug Discovery Goes Next
5/30/2023
AbbVie Bay Area Site Head and VP of Oncology Discovery Research Steve Davidsen, Ph.D. lays out the primary challenges to pushing forward in areas of high, unmet oncological need: accelerating discovery to shorten the time to patient impact and identifying optimal patients for a given mechanism of action or molecule.
-
Immunome’s Platform Partnership Potential
5/16/2023
Immunome’s discovery engine caught AbbVie’s eye, nabbing the biotech a transformative deal. CEO Purnanand Sarma, Ph.D. and CFO Corleen Roche take us behind the scenes.
-
Active ADC Space Challenges Development Strategies
5/15/2023
Payload and linker technology advances have contributed to an explosion in antibody-drug conjugate development in recent years, amd the funding has followed. But, while the face value of ADC activity represents a bright spot in an otherwise sluggish biotech investment environment, the challenges of doing business in a hotly competitive market are playing out.
-
Anatomy Of A Biopharma VC Deal
4/20/2023
Why does a venture capitalist choose to fund a biopharma company? What prompts them to choose not to? And why should (or shouldn't) a biopharma company take a VC's money?
-
Topical Biologics In Ophthalmology?
3/21/2023
A recent clinical study of an eyedrop formulated with Grifols’ Immunoglobulin-based Flebogamma DIF offers cause for optimism among multiple stakeholders. It could become the first-approved topically administered biologic therapy for dry eye disease.
-
AAV Manufacturing Field: An Interactive Look
3/17/2023
Mapping the adeno-associated virus (AAV) therapeutic space gives us a glimpse into indication priorities for gene therapy, and a look at whose got their fingers in which partners’ pots. Check out this interactive graphic from DeciBio Principal Carl Schoellhammer, Ph.D. It's not only instructive, its kind of therapeutic to play with.
-
Cashing In On Biopharma Collaboration
3/14/2023
How does a biopharma business that’s potentially years away from its first shot at therapeutic sales revenue thrive in a high-inflation, high-interest, supply-constrained business environment?